Merck and Schering-Plough said that they would pay $41.5 million to settle suits claiming they delayed study results on their cholesterol drug Vytorin because the data was unfavorable.

Kenilworth’s Schering-Plough (NYSE: SGP) said Wednesday the U.S. Attorney’s Office in New Jersey has closed its investigation of manufacturing practices at the company’s plants in Puerto ...

Kenilworth”s Schering-Plough (NYSE: SGP) said Thursday it plans to appeal a decision by the U.S. Federal Trade Commission that it and two other drug companies illegally kept cheaper versions of ...

TRENTON, N.J. — Merck & Co. is buying Schering-Plough Corp. for $41.1 billion in stock and cash in a deal that gives the companies more firepower to compete in a drug industry facing slumping ...

LOS ANGELES (MarketWatch) -- Drug maker Schering-Plough Corp. said Wednesday it plans to undertake a program designed to reap $1.5 billion in annual savings, or 10% of the company's cost base. In ...

A report prepared for Schering-Plough s Finance and Audit Committee confirmed that the swap-and-assign transactions effectively repatriated $728 million while deferring U.S. tax. The company's auditor ...

Schering-Plough shares fell 11 cents to $19.10 on the New York Stock Exchange. U.S.-traded shares of Bayer rose 47 cents to $26.39, also on the NYSE.

TRENTON, N.J. (AP) — Merck&Co. and Schering-Plough Corp. will hold special meetings in August for their stockholders to approve their pending merger, which would make the combined company ...

Schering-Plough was expected to earn 46 cents in 2003 and 59 cents in 2004, according to Thomson First Call. But Thursday night, the drugmaker warned that 2004 earnings likely would be lower than ...

Contacts Media: Merck David Caouette, 908-423-3461 or Schering-Plough Steve Galpin, 908-298-7415 Monique Mols, +31 (0) 412 66 5440 or Investors: Merck Eva Boratto or Carol Ferguson, 908-423-5185 ...

Merck& Co. is buying Schering-Plough Corp. for$41.1 billion in a deal that gives Merck key new businesses, access to a promising pipeline of new products and the chance to further ...

Schering and Merck Are Settling Vytorin Suits Merck and Schering-Plough said that they would pay $41.5 million to settle suits claiming they delayed study results on their cholesterol drug Vytorin ...